Peter Eckes, Former CTO of BASF Agricultural Solutions, to Chair Harpe Bioherbicide Board

Dr. Peter Eckes

Harpe Bioherbicide Solutions, Inc., an agricultural technology company focused on providing natural and sustainable herbicide solutions, announced today that Dr. Peter Eckes, former President of BASF leading Crop Protection R&D, Seed and Trait R&D and Regulatory in the Agricultural Solutions division, has joined its board and will serve as board chairperson.

Bill Buckner, CEO of Harpe Bioherbicide

“We’re thrilled to bring Peter’s vast, global experience developing and delivering innovation to our mission of creating new, natural weed control options for farmers and consumers.”

Through more than a 30-year career in the agricultural industry, Dr. Peter Eckes provides a unique appreciation for what it takes to bring innovation to the modern agriculture marketplace at scale without losing sight of farmer and consumer needs.

“Harpe has both a compelling value proposition and strong business plan to bring new and natural weed control innovations to life,” said Eckes. “I look forward to supporting and accelerating Harpe’s efforts to meet the critical need for the next generation of weed control and consumer demands for more natural inputs.”

Eckes assumes board leadership from Aidan J. Connolly, President of AgriTech Capital, who will remain as a Harpe Bioherbicide board member.

“As important as it is for a start-up to have a laser focus, fresh perspectives can make all the difference in the world,” said Connolly. “I’m working closely with Peter to ensure we make the most of his leadership and build on the momentum Harpe has achieved.”

Additional Board Members

Additional Harpe Bioherbicide board members include CEO Buckner; Kip Tom, CEO of Tom Farms and former UN Ambassador; Robb Fraley, former CTO for Monsanto Co.; Chad Brommer, Harpe Bioherbicide co-founder and CTO; and Daniel Pepitone, Harpe Bioherbicide co-founder and COO.

In addition to serving as Board chair, Eckes will lead the company’s scientific advisory committee, which includes Adrian Percy, Executive Director of the N.C. Plant Sciences Initiative at North Carolina State University; Stephen Powles, Professor at University of Western Australia; and Wesley Everman, Associate Professor and Extension Weed Specialist at North Carolina State University.

Through wide-spectrum control of broadleaf and grass seeds or weeds, the platform of Harpe Bioherbicide products will deliver new opportunities for organic agriculture through a series of all natural herbicide formulations for pre, post and desiccation use patterns. In addition, a series of tailored Harpe Bioherbicide pre and tank mix formulations will improve control of tough-to-kill weeds, including those resistant to current synthetic chemistries, facilitating the reduction, replacement, and enhancement of synthetic herbicides used in row and specialty crop, and commercial markets.

This year’s BioAgTech World Congress will be in Raleigh, April 23-26. 2024. Harpe is a candidate for the BioAgTech Innovator Award and World Congress Wi-Fi sponsor. Approximately 1300 attendees from 250 companies and 60 countries will be in attendance. Those attending are invited to visit Booth #22 to learn more about Harpe Bioherbicide formulations.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.